Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 

4-Traders Homepage  >  Equities  >  Euronext Paris  >  Sanofi    SAN   FR0000120578

SANOFI (SAN)

Delayed Quote. Delayed  - 08/24 05:35:11 pm
69.09 EUR   +0.33%
08/24 SANOFI : Haiti Impact Trip Provides Eye-Opening Experience for Stop ..
08/22 MEDIVATION : Pfizer propose 14 milliards de dollars pour racheter Me..
08/22 Pfizer to buy cancer drugmaker Medivation for $14 billion
SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsSector news 

Sanofi: Tests Show Zaltrap Improves Colorectal Cancer Survival Rate

share with twitter share with LinkedIn share with facebook
share via e-mail
0
10/08/2012 | 07:44am CEST

French drug company Sanofi SA (>> SANOFI) Monday said results from the pivotal Phase III Velour study evaluating Zaltrap showed improvement in overall survival rate to colorectal cancer.

MAIN FACTS:

- Sanofi said the Journal of Clinical Oncology published the results of the study evaluating Zaltrap effects.

- In the Velour trial evaluating metastatic colorectal cancer patients previously treated with an oxaliplatin-containing regimen, Zaltrap in combination with the Folfiri chemotherapy regimen (5-fluorouracil, leucovorin, irinotecan) showed a statistically significant improvement in overall survival, progression-free survival, and the overall tumor response rate versus placebo plus Folfiri.

- The Velour data supported the regulatory approval of Zaltrap by the U.S. Food and Drug Administration (FDA) on August 3, 2012 after a Priority Review.

- Zaltrap is under review at the European Medicines Agency and other regulatory agencies worldwide, Sanofi says.

-Write to Inti Landauro at inti.landauro@dowjones.com

Subscribe to WSJ: http://online.wsj.com?mod=djnwires

Stocks mentioned in the article : SANOFI
share with twitter share with LinkedIn share with facebook
share via e-mail
0
Latest news on SANOFI
08/24 SANOFI : Haiti Impact Trip Provides Eye-Opening Experience for Stop Hunger Now P..
08/22 MEDIVATION : Pfizer propose 14 milliards de dollars pour racheter Medivation
08/22 Pfizer to buy cancer drugmaker Medivation for $14 billion
08/22 Pfizer to buy Medivation and boost cancer drug portfolio
08/22 SANOFI : Provides Update on New Drug Application for Investigational Once-Daily ..
08/22 PHARMA MAJOR PFIZER OUTBIDS SANOFI T : Reports
08/22DJPfizer Near $14 Billion Deal for Biotech -- WSJ
08/21 SANOFI : Research center in Oro Valley looks to grow after spinoff from Sanofi
08/20 SANOFI : Zealand announces new timelines for a U.S. FDA decision on iGlarLixi, t..
08/19 SANOFI : Provides Update on New Drug Application for Investigational Once-Daily ..
More news
Sector news : Pharmaceuticals - NEC
08/24DJPFIZER : Buys Part of AstraZeneca's Antibiotics Business -- 2nd Update
08/24DJASTRAZENECA : Sells Part of its Antibiotics Business to Pfizer -- Update
08/24DJPfizer Buys Part of AstraZeneca's Antibiotics Business
08/24DJASTRAZENECA : Sells Part of Antibiotics Business to Pfizer for Up to $1.575 Bill..
08/23DJU.S. Lawmakers Plan Hearing Over Wave of Agriculture Mergers
More sector news : Pharmaceuticals - NEC
News from SeekingAlpha
08/24 PFIZER-MEDIVATION DEAL : Good Or Bad For Shareholders?
08/23 Who's Next After Medivation?
08/22 FDA OK of Sanofi's type 2 diabetes med iGlarLixi pushed out to November
08/22 Pfizer Pays Up
08/22 BIOTECH FORUM DAILY DIGEST : Will Medivation Ignite Takeover Wave? Is Acadia Nex..
Advertisement
Financials (€)
Sales 2016 36 960 M
EBIT 2016 9 286 M
Net income 2016 5 309 M
Debt 2016 5 008 M
Yield 2016 4,28%
P/E ratio 2016 15,72
P/E ratio 2017 14,32
EV / Sales 2016 2,54x
EV / Sales 2017 2,54x
Capitalization 88 761 M
More Financials
Chart SANOFI
Duration : Period :
Sanofi Technical Analysis Chart | SAN | FR0000120578 | 4-Traders
Full-screen chart
Technical analysis trends SANOFI
Short TermMid-TermLong Term
TrendsBearishNeutralBearish
Technical analysis
Income Statement Evolution
More Financials
Consensus
Sell
Buy
Mean consensus HOLD
Number of Analysts 23
Average target price 84,5 €
Spread / Average Target 23%
Consensus details
EPS Revisions
More Estimates Revisions
Managers
NameTitle
Olivier Brandicourt Chief Executive Officer & Director
Serge Weinberg Chairman
JÚr˘me Contamine Chief Financial Officer & EVP-Finance
Elias E. Zerhouni President-Global Research & Development
Yong-Jun Liu Head-Global Research & Development
More about the company
Sector and Competitors
1st jan.Capitalization (M$)
SANOFI-11.31%100 203
JOHNSON & JOHNSON16.28%326 773
ROCHE HOLDING LTD.-12.26%219 257
NOVARTIS AG-9.97%214 603
PFIZER INC.8.71%212 844
MERCK & CO., INC.20.37%175 812
More Results